Clinical Outcomes, Graft Longevity, and Chondral Protection Following Primary or Revision Meniscal Allograft Transplantation Surgery

MERCuRE (MEniscus, Restoration, Conservation, and Repair) Group Study on Clinical Outcomes, Graft Longevity, and Chondral Protection Following Primary or Revision Meniscal Allograft Transplantation Surgery

The MERCuRE (MEniscus, REstoration, Conservation, and Repair) group is embarking on a 20-year follow-up study to evaluate the clinical outcomes, graft longevity, and chondral protection following primary or revision Meniscal Allograft Transplantation surgery This clinical investigation is a prospective, primary observational, open-label, non-randomized, multi-center study. It is designed to collect clinical follow-up data on patients

Inclusion Criteria:

Subjects enrolled in this study must meet all of the following inclusion criteria:

• Males and females aged 10-65 years
• MRI or arthroscopic images confirming the suitability for meniscus transplantation.
• Patients undergoing an isolated primary/revision MAT (meniscal allograft transplant) procedure, or concomitant MAT with other knee procedures such as ligament reconstruction, realignment osteotomy, or cartilage resurfacing.
• Medically suitable for meniscus transplantation.
• Appropriate understanding of the language of the surgical center in terms of communication and reading.
• Ability of the Patient or parent/guardian to provide informed consent.

Exclusion Criteria:

• Inability to comply with rehabilitation programs.
• Patient aged less than 10 years and more than 65.
• Presence of diffuse full thickness cartilage loss (widespread ICRS Grade III-IV chondral damage) and/or architectural remodeling of bone (i.e. flattening of condyle) in the knee of interest.
• Significant medical comorbidities that limit patients from undergoing surgery.
• Presence of confounding neuromuscular, genetic/congenital, or post-traumatic conditions.